- Home
- FLNC vs IMCR Comparison
FLNC vs IMCR Comparison
Compare FLNC & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLNC
- IMCR
- Stock Information
- Founded
- FLNC 2018
- IMCR 2008
- Country
- FLNC United States
- IMCR United Kingdom
- Employees
- FLNC N/A
- IMCR N/A
- Industry
- FLNC Industrial Machinery/Components
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FLNC Miscellaneous
- IMCR Health Care
- Exchange
- FLNC Nasdaq
- IMCR Nasdaq
- Market Cap
- FLNC 2.4B
- IMCR 1.7B
- IPO Year
- FLNC 2021
- IMCR 2021
- Fundamental
- Price
- FLNC $22.01
- IMCR $32.93
- Analyst Decision
- FLNC Buy
- IMCR Buy
- Analyst Count
- FLNC 17
- IMCR 14
- Target Price
- FLNC $27.35
- IMCR $74.75
- AVG Volume (30 Days)
- FLNC 1.3M
- IMCR 267.8K
- Earning Date
- FLNC 11-26-2024
- IMCR 11-05-2024
- Dividend Yield
- FLNC N/A
- IMCR N/A
- EPS Growth
- FLNC N/A
- IMCR N/A
- EPS
- FLNC N/A
- IMCR N/A
- Revenue
- FLNC $2,143,395,000.00
- IMCR $280,914,000.00
- Revenue This Year
- FLNC $27.28
- IMCR $25.60
- Revenue Next Year
- FLNC $44.10
- IMCR $10.63
- P/E Ratio
- FLNC N/A
- IMCR N/A
- Revenue Growth
- FLNC 7.87
- IMCR 27.95
- 52 Week Low
- FLNC $12.74
- IMCR $29.72
- 52 Week High
- FLNC $27.80
- IMCR $76.98
- Technical
- Relative Strength Index (RSI)
- FLNC 53.21
- IMCR 52.76
- Support Level
- FLNC $20.00
- IMCR $31.10
- Resistance Level
- FLNC $21.65
- IMCR $35.47
- Average True Range (ATR)
- FLNC 0.96
- IMCR 1.49
- MACD
- FLNC -0.08
- IMCR 0.17
- Stochastic Oscillator
- FLNC 65.79
- IMCR 51.98
About FLNC Fluence Energy Inc.
Fluence Energy Inc is enabling the global clean energy transition with market-leading energy storage products and services, and digital applications for renewables and storage. Geographically, it derives a majority of its revenue from the Americas.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.